Respiratory Treatments Hit Hardest By HTA Terminations In England

 
• By Leela Barham

Exclusive analysis by the Pink Sheet explores how non-submissions by pharmaceutical companies to England’s health technology appraisal body are impacting the availability of medicines on the National Health Service.

Availability of respiratory disease treatments are affected by failure to submit evidence to NICE health technology appraisals in England. (Shutterstock)

More from Health Technology Assessment

More from United Kingdom